PI3K Delta Inhibitors Selective Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for selective inhibitors of PI3K delta to address diseases mediated by PI3K delta, particularly in cancer, inflammation, and autoimmune diseases, as current research has highlighted the enzyme's role in these conditions but lacks effective therapeutic options.
Innovation Solution
Development of specific compounds, such as those described in Formula I and Formula II, which inhibit PI3K delta activity, are used to treat various cancers, autoimmune diseases, and inflammatory diseases by modulating the enzyme's function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If selective PI3K delta inhibitors are developed to treat diseases mediated by PI3K delta, then therapeutic effectiveness is improved, but drug specificity and selectivity become critical challenges to avoid off-target effects
Solution Approach 1:
The patent applies local quality by designing the inhibitor molecule with specific functional groups positioned to interact with unique residues in the PI3K delta binding pocket. The compound features a heteroaryl amine moiety and a substituted phenyl ring with specific substituent patterns (R1-R6 groups) that create localized interactions with PI3K delta amino acid residues, enabling selective inhibition while avoiding off-target effects on other PI3K isoforms.
Solution Approach 2:
The patent employs parameter changes by systematically varying the chemical structure parameters of the inhibitor, including the heteroaryl ring type, amine substitution patterns, and phenyl ring substituents. By optimizing these molecular parameters, the compound achieves enhanced binding affinity and selectivity for PI3K delta compared to other PI3K isoforms, thereby improving therapeutic effectiveness while maintaining drug specificity.
2Reliability
If PI3K delta inhibitors are used to target uncontrolled cellular activities in cancer and inflammatory diseases, then disease treatment efficacy is improved, but potential side effects from affecting other cellular pathways may increase
Solution Approach 1:
The patent applies the intermediary principle by designing the PI3K delta inhibitor to act as a selective mediator that blocks the specific pro-inflammatory and pro-proliferative signaling pathways mediated by PI3K delta, while sparing other cellular pathways. The compound selectively inhibits PI3K delta-mediated phosphorylation events that drive inflammation and cancer progression, without significantly affecting other PI3K isoforms or unrelated cellular processes, thereby reducing potential side effects.
3Reliability
If novel chemical compounds are synthesized to achieve selective PI3K delta inhibition, then inhibitor potency is improved, but complexity of chemical synthesis and characterization increases
Solution Approach 1:
The patent applies segmentation by dividing the PI3K delta inhibitor into distinct molecular segments: a heteroaryl amine core structure, a connecting linker group, and a substituted phenyl ring with variable substituents (R1-R6). This segmented approach allows for modular synthesis where each segment can be prepared separately and then assembled, simplifying the overall synthesis process while maintaining the ability to optimize inhibitor potency through systematic variation of each segment.
Data Source
AI summary
The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.